Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Barry Rosenstein’s JANA Partners Moves on To Ashland Inc. (ASH)

Other diversified chemicals companies include Eastman Chemical Company (NYSE:EMN), FMC Corp (NYSE:FMC), Celanese Corporation (NYSE:CE), and Braskem SA (ADR) (NYSE:BAK). These peers are valued between 9 and 13 times their forward earnings estimates, meaning that the pricing of Ashland Inc. (NYSE:ASH)’s stock is very much in line with the rest of the industry. Eastman and FMC each experienced a double-digit increase in revenue in their most recent quarter compared to the same period in the previous year, potentially indicating that those businesses are in better shape than Ashland (we would note, however, that their trailing P/Es are fairly high; they only pull in line with the other chemical companies through expected improvements in earnings). Braskem pays a decent dividend yield, but it is actually unprofitable on a trailing basis and so we would avoid it from a value perspective. Celanese’s sales slipped a bit in its last quarterly report compared to the fourth quarter of 2011, though the stock is cheap enough that it might be fairly valued if the company can sustain its current performance.

Of course, we imagine that part of JANA’s investment thesis will involve some sort of special situation- the fund has bought up a large stake in the company very quickly, and so may push for some kind of transaction or merely want Ashland to return more cash to shareholders (the company does have about $500 million in cash on its balance sheet, or about 1 turn of EBITDA). As a result comparisons to similar companies, while they do show that Ashland’s valuation is reasonable as things stand compared to its peers, might underestimate the upside that Rosenstein and his team are seeking here.

Disclosure: I own no shares of any stocks mentioned in this article.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.